Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Initial Evaluation and Diagnosis of Medullary Thyroid Carcinoma

  • Chapter
  • First Online:
Medullary Thyroid Cancer

  • 655 Accesses

Abstract

Medullary Thyroid Carcinoma (MTC) is a neuroendocrine tumor arising from the neural crest parafollicular, or C-cells, of the thyroid. MTC is much less common than differentiated thyroid cancer (DTC), representing less than 5 % of thyroid malignancies diagnosed and has not had the same increase in incidence noted for DTC over the past decade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab. 2011;96(5):1237–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hahm JR, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11(1):73–80.

    Article  CAS  PubMed  Google Scholar 

  3. Herrmann BL, et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol. 2010;162(6):1141–5.

    Article  CAS  PubMed  Google Scholar 

  4. Iacobone M, et al. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg. 2002;26(8):886–90.

    Article  PubMed  Google Scholar 

  5. Costante G, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450–5.

    Article  CAS  PubMed  Google Scholar 

  6. Colombo C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab. 2012;97(3):905–13.

    Article  CAS  PubMed  Google Scholar 

  7. Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21(11):1199–207.

    Article  CAS  PubMed  Google Scholar 

  8. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31(4):468–74.

    Article  PubMed  Google Scholar 

  9. Pacini F, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.

    Article  CAS  PubMed  Google Scholar 

  10. Elisei R, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93(3):682–7.

    Article  CAS  PubMed  Google Scholar 

  11. Schilling T, et al. Prognostic value of codon 918 (ATG– > ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001;95(1):62–6.

    Article  CAS  PubMed  Google Scholar 

  12. Boichard A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012;97(10):E2031–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ciampi R, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23(1):50–7.

    Article  CAS  PubMed  Google Scholar 

  14. American Thyroid Association Guidelines Taskforce on Thyroid, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009. 19(11): p. 1167-214.

    Google Scholar 

  15. American Thyroid Association Guidelines Task, et al., Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009. 19(6): p. 565–612.

    Google Scholar 

  16. Machens A, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 2001;86(3):1104–9.

    CAS  PubMed  Google Scholar 

  17. Wells SA Jr, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Leboulleux S, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  19. Carlson KM, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet. 1994;55(6):1076–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Modigliani E, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998;48(3):265–73.

    Article  CAS  Google Scholar 

  21. Yip DT, et al. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery. 2011;150(6):1168–77.

    Article  PubMed  Google Scholar 

  22. Machens A, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–8.

    Article  PubMed  Google Scholar 

  23. Cooper DS, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.

    Article  PubMed  Google Scholar 

  24. Elisei R, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163–8.

    Article  CAS  PubMed  Google Scholar 

  25. Niccoli, P., et al., Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab. 1997;82(2): p. 338–41.

    Google Scholar 

  26. Hasselgren M, et al. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck. 2010;32(5):612–8.

    PubMed  Google Scholar 

  27. Papi G, et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest. 2006;29(5):427–37.

    Article  CAS  PubMed  Google Scholar 

  28. Rosario PW, et al. Usefulness of preoperative serum calcitonin in patients with nodular thyroid disease without suspicious history or cytology for medullary thyroid carcinoma. Arq Bras Endocrinol Metabol. 2013;57(4):312–6.

    Article  PubMed  Google Scholar 

  29. Vierhapper H, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid. 2005;15(11):1267–72.

    Article  CAS  PubMed  Google Scholar 

  30. Cheung K, et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab. 2008;93(6):2173–80.

    Article  CAS  PubMed  Google Scholar 

  31. Cohen R, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85(2):919–22.

    Article  CAS  PubMed  Google Scholar 

  32. Machens A, et al. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer. 2009;16(4):1291–8.

    Article  CAS  PubMed  Google Scholar 

  33. Mian C, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab. 2014;99(5):1656–64.

    Article  CAS  PubMed  Google Scholar 

  34. Rink T, et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid. 2009;19(4):327–32.

    Article  CAS  PubMed  Google Scholar 

  35. Chambon G, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab. 2011;96(1):75–81.

    Article  CAS  PubMed  Google Scholar 

  36. Milone F, et al. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf). 2010;73(1):85–8.

    CAS  Google Scholar 

  37. Frank-Raue K, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid. 2013;23(3):294–300.

    Article  CAS  PubMed  Google Scholar 

  38. Elisei R, Romei C. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. Thyroid Res. 2013;6(Suppl 1):S2.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Niccoli P, et al. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur J Endocrinol. 1995;132(1):75–81.

    Article  CAS  PubMed  Google Scholar 

  40. Kratzsch J, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem. 2011;57(3):467–74.

    Article  CAS  PubMed  Google Scholar 

  41. Algeciras-Schimnich A, et al. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009;94(3):861–8.

    Article  CAS  PubMed  Google Scholar 

  42. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab. 2014;99(8):2986–94.

    Article  CAS  PubMed  Google Scholar 

  43. Walter MA, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010;116(1):31–40.

    CAS  PubMed  Google Scholar 

  44. Fukushima M, et al. Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule. World J Surg. 2009;33(5):963–8.

    Article  PubMed  Google Scholar 

  45. Lee S, et al. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. AJR Am J Roentgenol. 2010;194(4):1090–4.

    Article  PubMed  Google Scholar 

  46. Trimboli P, et al. Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res. 2014;33:87.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Andrioli M, et al. Elastographic presentation of medullary thyroid carcinoma. Endocrine. 2014;45(1):153–5.

    Article  CAS  PubMed  Google Scholar 

  48. Marcus C, et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202(6):1316–29.

    Article  PubMed  Google Scholar 

  49. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2655–63.

    Article  CAS  PubMed  Google Scholar 

  50. Trimboli P, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf). 2015;82(2):280–5.

    Article  Google Scholar 

  51. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91(1):56–60.

    Article  PubMed  Google Scholar 

  52. Mirallie E, et al. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol. 2004;30(7):790–5.

    Article  CAS  PubMed  Google Scholar 

  53. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 2000;22(6):351–8.

    Article  CAS  PubMed  Google Scholar 

  54. Trimboli P, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf). 2014;80(1):135–40.

    Article  CAS  Google Scholar 

  55. Diazzi C, et al. The diagnostic value of calcitonin measurement in wash-out fluid from fine-needle aspiration of thyroid nodules in the diagnosis of medullary thyroid cancer. Endocr Pract. 2013;19(5):769–79.

    Article  PubMed  Google Scholar 

  56. Kudo T, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid. 2007;17(7):635–8.

    Article  PubMed  Google Scholar 

  57. Elisei R, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92(12):4725–9.

    Article  CAS  PubMed  Google Scholar 

  58. Eng C, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosom Cancer. 1995;12(3):209–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General and Gastrointestinal Surgery, Massachusetts General Hospital, 15 Parkman Street, Wang ACC 460, Boston, MA, 02114, USA

    Abbey Fingeret

  2. Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7B, Boston, MA, 02114, USA

    Carrie C. Lubitz

Authors
  1. Abbey Fingeret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carrie C. Lubitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Abbey Fingeret or Carrie C. Lubitz .

Editor information

Editors and Affiliations

  1. Associate Professor of Surgery; Chief, Section of Endocrine Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Tracy S. Wang

  2. Donald C. Ausman Family Foundation Professor in Surgery and Chair, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Douglas B. Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fingeret, A., Lubitz, C.C. (2016). Initial Evaluation and Diagnosis of Medullary Thyroid Carcinoma. In: Wang, T., Evans, D. (eds) Medullary Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-39412-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39412-1_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39410-7

  • Online ISBN: 978-3-319-39412-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation